



Product Information

Product ID N1868

CAS No. 698387-09-6

Chemical Name (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide

Synonym HKI-272, WAY-179272

Formula C₃₀H₂₉ClN₆O₃

Formula Wt. 557.04

Melting Point


Purity ≥98%

Solubility

Store Temp Ambient

Ship Temp Ambient

Description Neratinib is an irreversible EGFR inhibitor that displays anticancer chemotherapeutic benefit in the treatment of HER2 positive breast cancers and non-small cell lung cancer (NSCLC). Neratinib prevents ligand-induced receptor dimerization by targeting a cysteine residue in the ATP binding pocket of the receptor. In pre-clinical models, this compound induces cell cycle arrest and decreases cell proliferation.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
N1868	1 mg	\$97.70
N1868	5 mg	\$172.60
N1868	10 mg	\$293.20
N1868	25 mg	\$525.90
N1868	100 mg	\$1499.40

References López-Tarruella S, Jerez Y, Márquez-Rodas I, et al. Neratinib (HKI-272) in the treatment of breast cancer. *Future Oncol.* 2012 Jun;8(6):671-81. PMID: 22764764.

Sánchez-Martín M, Pandiella A. Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications. *Int J Cancer.* 2012 Jul 1;131(1):244-52. PMID: 21826647.

Wong KK, Fracasso PM, Bukowski RM, et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. *Clin Cancer Res.* 2009 Apr 1;15(7):2552-8. PMID: 19318484.

Rabindran SK, Discafani CM, Rosfjord EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. *Cancer Res.* 2004 Jun 1;64(11):3958-65. PMID: 1517300.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.